West Pharmaceutical Sells SmartDose Rights To AbbVie And Refocuses Portfolio

• West Pharmaceutical Services (NYSE:WST) has agreed to sell all manufacturing and supply rights for its SmartDose 3.5mL On Body Delivery System to AbbVie.
• The deal covers only the 3.5mL version; West will continue to supply other SmartDose configurations.
• The agreement represents a notable shift in West’s product portfolio and its role in large volume drug delivery partnerships.

For you as an investor, this move sits at the core of what West does as a provider of drug delivery and packaging solutions to pharmaceutical and biotech clients. The SmartDose platform is part of a broader push toward wearable injectors and at home administration of complex therapies, a trend that many drug developers are working on.

The transfer of manufacturing and supply rights for the 3.5mL system to AbbVie changes how future SmartDose related revenue could flow between the two companies. It also clarifies that West remains involved with other SmartDose versions, which may matter for how you think about product concentration, partnership risk, and long term positioning in on body delivery devices.

Stay updated on the most important news stories for West Pharmaceutical Services by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on West Pharmaceutical Services.

How West Pharmaceutical Services stacks up against its biggest competitors

The $112.5 million sale of SmartDose 3.5mL manufacturing and supply rights to AbbVie concentrates West’s role in on body delivery around larger volume systems and other SmartDose variants, while still keeping it involved with the 3.5mL product until close. With SmartDose 3.5mL expected to represent about 4% of 2025 revenue, the deal size relative to that contribution, plus potential milestone payments before closing in mid 2026, gives you a clearer sense of how management is reshaping the portfolio while reinforcing a key pharma relationship.

West Pharmaceutical Services Narrative: how this deal could reshape the story

This agreement may influence how investors frame West as a partner to large pharma, with AbbVie taking on more direct control of one device configuration while West continues to focus on broader injectable and wearable platforms like the SmartDose 10mL system and the Synchrony S1 prefillable syringe. If you have been following the story as a pure play on complex drug delivery, this move could be viewed as a shift toward a wider mix of systems rather than reliance on a single on body product.

Risks and rewards to keep in mind

• Upfront consideration of $112.5 million plus potential pre close milestone payments provides liquidity that can be redeployed across West’s containment and delivery portfolio.
• West retains development and manufacturing of other SmartDose versions and is expanding offerings like the Synchrony S1 system, which supports a broader customer base in biologics and vaccines.
• Transferring rights to a product expected to contribute about 4% of 2025 revenue introduces some product mix change that investors will need to watch as 2026 guidance is detailed.
• The deal is subject to closing conditions and timing around mid 2026, so there is execution risk around both the transaction and West’s ongoing project commitments up to closing.

What to watch next

From here, the key things to watch are how West frames 2026 guidance on its fourth quarter 2025 call, the progression of any milestone payments before close, and early traction for newer platforms like Synchrony S1 alongside the remaining SmartDose configurations. If you want to see how other investors are interpreting moves like this across the sector, you can check out community narratives on this page and compare different takes on where West fits in the wider drug delivery space.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com